➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Express Scripts
Baxter
Mallinckrodt

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 9,567,591

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,567,591
Title:Generation of human embryonic stem-like cells using intronic RNA
Abstract: This invention generally relates to a method for developing, generating and selecting human embryonic stem (hES)-like pluripotent cells using transgenic expression of intronic microRNA-like RNA agents. More particularly, the present invention relates to a method and composition for generating a non-naturally occurring intron and its intronic components capable of being processed into mir-302-like RNA molecules in mammalian cells and thus inducing certain specific gene silencing effects on differentiation-related and fate-determinant genes of the cells, resulting in reprogramming the cells into a pluripotent embryonic stem (ES)-cell-like state. The ES-like cells so obtained are strongly express hES cell markers, such as Oct3/4, SSEA-3 and SSEA-4, and can be guided into various tissue cell types by treating certain hormones and/or growth factors under a feeder-free cell culture condition in vitro, which may be used for transplantation and gene therapies. Therefore, the present invention offers a simple, effective and safe gene manipulation approach for not only reprogramming somatic cells into ES-like pluripotent cells but also facilitating the maintenance of pluripotent and renewal properties of ES cells under a feeder-free cell culture condition, preventing the tedious retroviral insertion of four large transcription factor genes into one single cell as used in the previous iPS methods.
Inventor(s): Lin; Shi-Lung (Arcadia, CA), Ying; Shao-Yao (San Marino, CA), Wu; David Ts (Taipei, TW)
Assignee: MELLO BIOTECHNOLOGY, INC. (Santa Fe Springs, CA) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, CA)
Application Number:12/149,725
Patent Claims:see list of patent claims

Details for Patent 9,567,591

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial MELLO BIOTECHNOLOGY, INC. (Santa Fe Springs, CA) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, CA) 2023-05-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial MELLO BIOTECHNOLOGY, INC. (Santa Fe Springs, CA) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, CA) 2023-05-15 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial MELLO BIOTECHNOLOGY, INC. (Santa Fe Springs, CA) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, CA) 2023-05-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Johnson and Johnson
McKesson
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.